Opinion | Aflac's Unorthodox Ascent
The insurer saw sales double in three years after gambling on ads with a quacking duck.
Aflac (AFL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Aflac (AFL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Accident & Health Insurance Stocks to Watch Amid Pricing Pressure
Accident and Health Insurance stocks like AFL, TRUP and GL are set to gain from rising underwriting exposure and accelerated digitalization. However, pricing pressure is a concern given rising medical costs and inflation.
3 Dividend Growth Stocks That Can Double Your Income
Many investors focus on the dividend yield, but not much on the dividend growth.
Aflac: Best-In-Class Life Insurer Poised To Benefit From A Steepening Yield Curve
Buy Aflac for its high-interest rate sensitivity, superior financial strength, and best-in-class capital return strategy amid a steepening yield curve. Aflac's dominant Japan exposure, iconic brand, low debt/equity, and consistent dividend growth set it apart from peers like MetLife and Prudential. AFL offers a compelling 2.5x risk/reward to a $120 target (vs. $102 stop), supported by historical outperformance and a temporary slowdown in price momentum.
Aflac: Q2 Earnings Indicate Slowing Growth (Rating Downgrade)
I am downgrading AFL to a hold due to slowing revenue and earnings growth and a premium valuation versus peers. AFL's Q2 results showed declining revenue and EPS, with investment losses and Japan segment weakness offsetting US segment growth. Despite a strong balance sheet and impressive dividend growth history, current valuation metrics limit near-term upside potential.
All You Need to Know About Aflac (AFL) Rating Upgrade to Buy
Aflac (AFL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aflac Loads the Buyback Cannon as New Sales Signal Strength
AFL boosts its buyback plan to 130.9M shares as strong sales in Japan and higher U.S. margins fuel shareholder returns.
Aflac Q2 Earnings Beat Estimates on Solid Cancer Product Sales
AFL's Q2 earnings benefit from robust Japan cancer insurance sales and strong persistency rates in the U.S. business, partly offset by rising costs.
Aflac Incorporated (AFL) Q2 2025 Earnings Call Transcript
Aflac Incorporated (NYSE:AFL ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Daniel Paul Amos - Chairman & CEO David Young - Corporate Participant Koichiro Yoshizumi - Senior Managing Exec. Officer and Asst.
Here's What Key Metrics Tell Us About Aflac (AFL) Q2 Earnings
While the top- and bottom-line numbers for Aflac (AFL) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aflac (AFL) Q2 Earnings and Revenues Top Estimates
Aflac (AFL) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.83 per share a year ago.
